Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

• DOI: 10.1007/s40120-021-00271-2
• Publication Date: 2021-08-16T18:02:57Z
• Authors: Jiachen Gu; Zongshan Li; Huimin Chen; Xiaomin Xu; Yongang Li; Yaxing Gui
• Keywords: Tolerability

Amyloid-beta (Aβ) protein is a major component of the extracellular plaque found in brains individuals with Alzheimer's disease (AD). In this study, we investigated effect trans-resveratrol as an antagonist treatment for moderate to mild AD, well its safety and tolerability. This was case–control study that enrolled 30 selected patients who had been clinically diagnosed AD. These were randomly divided into two groups, namely, placebo group (n = 15) received 500 mg orally once daily 52 weeks. Brain magnetic resonance imaging (MRI) examinations performed on cerebrospinal fluid (CSF) samples obtained from all participants before (baseline) after (52 weeks). Enzyme-linked immunosorbent assays used determine levels plasma Aβ40 Aβ42 CSF Aβ42. The results showed changes over period blood treated not statistically significant (P > 0.05). contrast, decrease compared at beginning (CSF Aβ40: P 0.024, 0.036). Analysis images brain MRI scans revealed volume significantly reduced weeks 0.011) group, Further analysis indicated level matrix metallopeptidase 9 decreased by 46% 0.033). indicate has potential neuroprotective roles AD mechanism may involve reduction accumulation toxicity Aβ patients, thereby reducing neuroinflammation. Chinese clinical trial registry: CTR20151780X.